Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. While frontline chemotherapy regimens are generally very effective, the prognosis for patients whose leukemia returns remains poor. The presence of measurable residual disease (MRD) in bone marrow at the completion of induct...
Gespeichert in:
Veröffentlicht in: | Cancers 2020-01, Vol.12 (1), p.169 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 169 |
container_title | Cancers |
container_volume | 12 |
creator | Jo, Sumin Fotovati, Abbas Duque-Afonso, Jesus Cleary, Michael L van den Elzen, Peter Seif, Alix E Reid, Gregor S D |
description | Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. While frontline chemotherapy regimens are generally very effective, the prognosis for patients whose leukemia returns remains poor. The presence of measurable residual disease (MRD) in bone marrow at the completion of induction therapy is the strongest predictor of relapse, suggesting that strategies to eliminate the residual leukemic blasts from this niche could reduce the incidence of recurrence. We have previously reported that toll-like receptor (TLR) agonists achieve durable T cell-mediated protection in transplantable cell line-based models of B cell precursor leukemia (B-ALL). However, the successful application of TLR agonist therapy in an MRD setting would require the induction of anti-leukemic immune activity specifically in the bone marrow, a site of the chemotherapy-resistant leukemic blasts. In this study, we compare the organ-specific depletion of human and mouse primary B-ALL cells after systemic administration of endosomal TLR agonists. Despite comparable splenic responses, only the TLR9 agonist induced strong innate immune responses in the bone marrow and achieved a near-complete elimination of B-ALL cells. This pattern of response was associated with the most significantly prolonged disease-free survival. Overall, our findings identify innate immune activity in the bone marrow that is associated with durable TLR-induced protection against B-ALL outgrowth. |
doi_str_mv | 10.3390/cancers12010169 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7016792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2547620946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-fea9e221134246301ef4970a420436566288fee8cad1a2c0a2a61a855855e5e73</originalsourceid><addsrcrecordid>eNpdUV1LHTEQDdKicvW5byXgS19W87Gb3bwI188Wtghqn8M0O9HIbnJN9rb47434gToEZmDOOczJIeQbZ_tSanZgIVhMmQvGGVd6g2wL1opKKV1_eTdvkd2c71gpKXmr2k2yJQulEbrbJuOJdw4ThtnDSE9wNeLsY6DR0aMYkP6GlOJ_eonZDwVEj6pl31NwMyZ69ZBnnLyly2Hywec5wSv3NAwxx6lIXveXdHkTn9Z5h3x1MGbcfekL8ufs9Pr4Z9VfnP86XvaVrQWfK4egUQjOZS1qJRlHV-uWQS1YLVWjlOg6h9hZGDgIy0CA4tA1TXnYYCsX5PBZd7X-O-Fgy-EJRrNKfoL0YCJ483ET_K25if9MW_6x1aII_HgRSPF-jXk2k88WxxECxnU2QjZMM6kUK9C9T9C7uE6h2DOiqVslmC4eFuTgGWVTzDmhezuGM_MUpvkUZmF8f-_hDf8anXwEXHybjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547620946</pqid></control><display><type>article</type><title>Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Jo, Sumin ; Fotovati, Abbas ; Duque-Afonso, Jesus ; Cleary, Michael L ; van den Elzen, Peter ; Seif, Alix E ; Reid, Gregor S D</creator><creatorcontrib>Jo, Sumin ; Fotovati, Abbas ; Duque-Afonso, Jesus ; Cleary, Michael L ; van den Elzen, Peter ; Seif, Alix E ; Reid, Gregor S D</creatorcontrib><description>Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. While frontline chemotherapy regimens are generally very effective, the prognosis for patients whose leukemia returns remains poor. The presence of measurable residual disease (MRD) in bone marrow at the completion of induction therapy is the strongest predictor of relapse, suggesting that strategies to eliminate the residual leukemic blasts from this niche could reduce the incidence of recurrence. We have previously reported that toll-like receptor (TLR) agonists achieve durable T cell-mediated protection in transplantable cell line-based models of B cell precursor leukemia (B-ALL). However, the successful application of TLR agonist therapy in an MRD setting would require the induction of anti-leukemic immune activity specifically in the bone marrow, a site of the chemotherapy-resistant leukemic blasts. In this study, we compare the organ-specific depletion of human and mouse primary B-ALL cells after systemic administration of endosomal TLR agonists. Despite comparable splenic responses, only the TLR9 agonist induced strong innate immune responses in the bone marrow and achieved a near-complete elimination of B-ALL cells. This pattern of response was associated with the most significantly prolonged disease-free survival. Overall, our findings identify innate immune activity in the bone marrow that is associated with durable TLR-induced protection against B-ALL outgrowth.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12010169</identifier><identifier>PMID: 32015298</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acute lymphoblastic leukemia ; Agonists ; Bone marrow ; Cell culture ; Chemotherapy ; Cytotoxicity ; Induction therapy ; Innate immunity ; Leukemia ; Lymphatic leukemia ; Lymphocytes ; Lymphocytes T ; Malignancy ; Medical prognosis ; Patients ; Pediatrics ; Spleen ; TLR9 protein ; Toll-like receptors</subject><ispartof>Cancers, 2020-01, Vol.12 (1), p.169</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-fea9e221134246301ef4970a420436566288fee8cad1a2c0a2a61a855855e5e73</citedby><cites>FETCH-LOGICAL-c421t-fea9e221134246301ef4970a420436566288fee8cad1a2c0a2a61a855855e5e73</cites><orcidid>0000-0003-3739-6734 ; 0000-0002-1799-2582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32015298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jo, Sumin</creatorcontrib><creatorcontrib>Fotovati, Abbas</creatorcontrib><creatorcontrib>Duque-Afonso, Jesus</creatorcontrib><creatorcontrib>Cleary, Michael L</creatorcontrib><creatorcontrib>van den Elzen, Peter</creatorcontrib><creatorcontrib>Seif, Alix E</creatorcontrib><creatorcontrib>Reid, Gregor S D</creatorcontrib><title>Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. While frontline chemotherapy regimens are generally very effective, the prognosis for patients whose leukemia returns remains poor. The presence of measurable residual disease (MRD) in bone marrow at the completion of induction therapy is the strongest predictor of relapse, suggesting that strategies to eliminate the residual leukemic blasts from this niche could reduce the incidence of recurrence. We have previously reported that toll-like receptor (TLR) agonists achieve durable T cell-mediated protection in transplantable cell line-based models of B cell precursor leukemia (B-ALL). However, the successful application of TLR agonist therapy in an MRD setting would require the induction of anti-leukemic immune activity specifically in the bone marrow, a site of the chemotherapy-resistant leukemic blasts. In this study, we compare the organ-specific depletion of human and mouse primary B-ALL cells after systemic administration of endosomal TLR agonists. Despite comparable splenic responses, only the TLR9 agonist induced strong innate immune responses in the bone marrow and achieved a near-complete elimination of B-ALL cells. This pattern of response was associated with the most significantly prolonged disease-free survival. Overall, our findings identify innate immune activity in the bone marrow that is associated with durable TLR-induced protection against B-ALL outgrowth.</description><subject>Acute lymphoblastic leukemia</subject><subject>Agonists</subject><subject>Bone marrow</subject><subject>Cell culture</subject><subject>Chemotherapy</subject><subject>Cytotoxicity</subject><subject>Induction therapy</subject><subject>Innate immunity</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Spleen</subject><subject>TLR9 protein</subject><subject>Toll-like receptors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUV1LHTEQDdKicvW5byXgS19W87Gb3bwI188Wtghqn8M0O9HIbnJN9rb47434gToEZmDOOczJIeQbZ_tSanZgIVhMmQvGGVd6g2wL1opKKV1_eTdvkd2c71gpKXmr2k2yJQulEbrbJuOJdw4ThtnDSE9wNeLsY6DR0aMYkP6GlOJ_eonZDwVEj6pl31NwMyZ69ZBnnLyly2Hywec5wSv3NAwxx6lIXveXdHkTn9Z5h3x1MGbcfekL8ufs9Pr4Z9VfnP86XvaVrQWfK4egUQjOZS1qJRlHV-uWQS1YLVWjlOg6h9hZGDgIy0CA4tA1TXnYYCsX5PBZd7X-O-Fgy-EJRrNKfoL0YCJ483ET_K25if9MW_6x1aII_HgRSPF-jXk2k88WxxECxnU2QjZMM6kUK9C9T9C7uE6h2DOiqVslmC4eFuTgGWVTzDmhezuGM_MUpvkUZmF8f-_hDf8anXwEXHybjQ</recordid><startdate>20200110</startdate><enddate>20200110</enddate><creator>Jo, Sumin</creator><creator>Fotovati, Abbas</creator><creator>Duque-Afonso, Jesus</creator><creator>Cleary, Michael L</creator><creator>van den Elzen, Peter</creator><creator>Seif, Alix E</creator><creator>Reid, Gregor S D</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3739-6734</orcidid><orcidid>https://orcid.org/0000-0002-1799-2582</orcidid></search><sort><creationdate>20200110</creationdate><title>Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists</title><author>Jo, Sumin ; Fotovati, Abbas ; Duque-Afonso, Jesus ; Cleary, Michael L ; van den Elzen, Peter ; Seif, Alix E ; Reid, Gregor S D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-fea9e221134246301ef4970a420436566288fee8cad1a2c0a2a61a855855e5e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Agonists</topic><topic>Bone marrow</topic><topic>Cell culture</topic><topic>Chemotherapy</topic><topic>Cytotoxicity</topic><topic>Induction therapy</topic><topic>Innate immunity</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Spleen</topic><topic>TLR9 protein</topic><topic>Toll-like receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jo, Sumin</creatorcontrib><creatorcontrib>Fotovati, Abbas</creatorcontrib><creatorcontrib>Duque-Afonso, Jesus</creatorcontrib><creatorcontrib>Cleary, Michael L</creatorcontrib><creatorcontrib>van den Elzen, Peter</creatorcontrib><creatorcontrib>Seif, Alix E</creatorcontrib><creatorcontrib>Reid, Gregor S D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jo, Sumin</au><au>Fotovati, Abbas</au><au>Duque-Afonso, Jesus</au><au>Cleary, Michael L</au><au>van den Elzen, Peter</au><au>Seif, Alix E</au><au>Reid, Gregor S D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2020-01-10</date><risdate>2020</risdate><volume>12</volume><issue>1</issue><spage>169</spage><pages>169-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. While frontline chemotherapy regimens are generally very effective, the prognosis for patients whose leukemia returns remains poor. The presence of measurable residual disease (MRD) in bone marrow at the completion of induction therapy is the strongest predictor of relapse, suggesting that strategies to eliminate the residual leukemic blasts from this niche could reduce the incidence of recurrence. We have previously reported that toll-like receptor (TLR) agonists achieve durable T cell-mediated protection in transplantable cell line-based models of B cell precursor leukemia (B-ALL). However, the successful application of TLR agonist therapy in an MRD setting would require the induction of anti-leukemic immune activity specifically in the bone marrow, a site of the chemotherapy-resistant leukemic blasts. In this study, we compare the organ-specific depletion of human and mouse primary B-ALL cells after systemic administration of endosomal TLR agonists. Despite comparable splenic responses, only the TLR9 agonist induced strong innate immune responses in the bone marrow and achieved a near-complete elimination of B-ALL cells. This pattern of response was associated with the most significantly prolonged disease-free survival. Overall, our findings identify innate immune activity in the bone marrow that is associated with durable TLR-induced protection against B-ALL outgrowth.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32015298</pmid><doi>10.3390/cancers12010169</doi><orcidid>https://orcid.org/0000-0003-3739-6734</orcidid><orcidid>https://orcid.org/0000-0002-1799-2582</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2020-01, Vol.12 (1), p.169 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7016792 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
subjects | Acute lymphoblastic leukemia Agonists Bone marrow Cell culture Chemotherapy Cytotoxicity Induction therapy Innate immunity Leukemia Lymphatic leukemia Lymphocytes Lymphocytes T Malignancy Medical prognosis Patients Pediatrics Spleen TLR9 protein Toll-like receptors |
title | Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20Depletion%20of%20Bone%20Marrow%20Resident%20B-ALL%20after%20Systemic%20Administration%20of%20Endosomal%20TLR%20Agonists&rft.jtitle=Cancers&rft.au=Jo,%20Sumin&rft.date=2020-01-10&rft.volume=12&rft.issue=1&rft.spage=169&rft.pages=169-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12010169&rft_dat=%3Cproquest_pubme%3E2547620946%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547620946&rft_id=info:pmid/32015298&rfr_iscdi=true |